Here's Why Vanguard's Worst-Performing Sector ETF Is a No-Brainer Buy Right Now
Healthcare Sector Performance: The healthcare sector, particularly the Vanguard Healthcare ETF, is experiencing significant sell-offs due to underperformance compared to other sectors like technology and consumer discretionary, largely influenced by issues with major companies like UnitedHealth Group and a general shift in investor focus towards growth-oriented sectors.
Investment Strategy: Despite current challenges, the Vanguard Healthcare ETF presents a compelling investment opportunity for long-term investors seeking diversification and lower costs, as it offers a low expense ratio and attractive valuation metrics, making it suitable for those looking to balance their portfolios.
Trade with 70% Backtested Accuracy
Analyst Views on VHT
About the author
This ETF Demonstrates the Genuine Recovery in Healthcare
Health Sector Performance: The healthcare sector has struggled recently, with notable losses for companies like United Health Group and Novo Nordisk, but has shown signs of recovery with a 19% gain over the past six months.
Weight Loss Drug Adoption: The popularity of weight loss treatments, particularly GLP-1 agonists like Ozempic and Wegovy, is driving growth in the healthcare market, with expectations for continued expansion in the coming years.
Market Valuation Trends: Low valuations in the healthcare sector are attracting investor interest, as firms shift from injectable to pill forms of treatments, indicating a potential for increased profitability.
Investment Recommendations: Analysts suggest that undervalued stocks in the healthcare sector present buying opportunities, with a focus on companies that are expected to benefit from the ongoing trends in health treatments and market recovery.
The 10 Best Performing Healthcare Stocks of the Year So Far as the Sector Remains Stable
Healthcare Index Performance: The S&P healthcare index (XLV) showed moderate gains of 13%-14% in 2025, with a year-to-date increase of 12.2%, but underperformed compared to the broader S&P 500, which exceeded 15%-20% returns due to strong performance in technology and other sectors.
Top Performing Healthcare Stocks: Regencell Bioscience (RGC) led the healthcare stocks with an extraordinary YTD performance of +15,138.46%, followed by ABIVAX Société Anonyme (ABVX) and Cidara Therapeutics (CDTX) with +1,470.22% and +721.43%, respectively.
Quant Ratings Overview: GRAIL (GRAL) and Nuvation Bio (NUVB) received Strong Buy ratings with scores of 4.98 and 4.99, while most other companies in the top 10 list carried Hold ratings, indicating a mixed outlook for the sector.
Healthcare ETFs Mentioned: Various healthcare ETFs such as XLV, VHT, IHI, IXJ, IYH, FHLC, and FXH were noted, highlighting investment options within the healthcare sector.
Health Care ETFs Remain Unfazed by Price Reductions from Major Pharmaceutical Companies
Impact of Drug Pricing Deals: Big pharmaceutical companies are negotiating with the U.S. government to lower Medicaid drug prices, but analysts believe the financial impact on these companies may be less severe than initially feared.
Medicaid's Role in Drug Pricing: Medicaid accounts for about 10% of U.S. prescription drug spending and often secures significant discounts, which helps mitigate concerns over pricing pressures on pharmaceutical companies.
Resilience of Health Care ETFs: Diversified health care ETFs, such as the Health Care Select Sector SPDR Fund and Vanguard Health Care ETF, are performing well and provide a buffer against potential volatility from drug pricing news.
Pharma-Specific ETFs and Diversification: While specialized pharmaceutical ETFs may face more direct impacts from pricing negotiations, their diversified structures help reduce risks associated with individual companies, allowing them to remain stable amidst market fluctuations.
Healthcare ETFs Outperform Tech, Attract Billions as Investors Exit Due to Bubble Concerns
Healthcare Sector Rotation: A significant shift towards healthcare investments is occurring globally, with investors favoring sector ETFs, particularly in biotech and pharma, driven by strong performance in clinical trials and AI advancements.
Impact of Eli Lilly: Eli Lilly's recent achievement of a $1 trillion market cap has sparked enthusiasm in the healthcare sector, with its innovative products leading to substantial revenue growth and reshaping market expectations.
AI Integration in Healthcare: The integration of AI in healthcare is proving beneficial, with major companies like Lilly and Johnson & Johnson leveraging AI technologies to enhance drug discovery and surgical procedures, attracting investor interest in healthcare ETFs.
Sustained Investor Interest: The current healthcare investment trend reflects a recalibration rather than a temporary safety trade, as the sector combines defensiveness, innovation, and strong earnings momentum, making healthcare ETFs the primary beneficiaries.
Nasdaq Sees Strongest Performance Since May, Fueled by Alphabet's AI Surge: Implications for Thanksgiving Week Ahead.
Market Performance: U.S. stocks experienced a significant rebound on Monday, with the Nasdaq Composite index achieving its best performance since May, gaining 2.7%.
Recent Gains: The Nasdaq has seen a total increase of 3.6% since the market opened on Friday, marking its strongest two-day performance since mid-May.
CDC webpage states that the claim 'Vaccines do not cause autism' lacks evidence-based support.
CDC Webpage Update: The CDC has revised its webpage to indicate that vaccines may potentially contribute to autism, stating that previous claims asserting vaccines do not cause autism are not evidence-based and warrant further investigation.
Ongoing Investigations: The Department of Health and Human Services is conducting a comprehensive assessment of autism causes, exploring biological mechanisms that may link early childhood vaccinations to autism, including factors like aluminum adjuvants and neuroinflammation.
Political Context: The revision of the webpage comes amid political discussions, particularly during Health Secretary Robert F. Kennedy Jr.’s Senate confirmation process, where he assured that the CDC would not remove statements denying a vaccine-autism link.
Trust in CDC: The changes have raised concerns about the CDC's credibility as a scientific authority, leading to resignations of senior officials who cited the politicization of science within the agency.
This ETF Demonstrates the Genuine Recovery in Healthcare
Health Sector Performance: The healthcare sector has struggled recently, with notable losses for companies like United Health Group and Novo Nordisk, but has shown signs of recovery with a 19% gain over the past six months.
Weight Loss Drug Adoption: The popularity of weight loss treatments, particularly GLP-1 agonists like Ozempic and Wegovy, is driving growth in the healthcare market, with expectations for continued expansion in the coming years.
Market Valuation Trends: Low valuations in the healthcare sector are attracting investor interest, as firms shift from injectable to pill forms of treatments, indicating a potential for increased profitability.
Investment Recommendations: Analysts suggest that undervalued stocks in the healthcare sector present buying opportunities, with a focus on companies that are expected to benefit from the ongoing trends in health treatments and market recovery.
The 10 Best Performing Healthcare Stocks of the Year So Far as the Sector Remains Stable
Healthcare Index Performance: The S&P healthcare index (XLV) showed moderate gains of 13%-14% in 2025, with a year-to-date increase of 12.2%, but underperformed compared to the broader S&P 500, which exceeded 15%-20% returns due to strong performance in technology and other sectors.
Top Performing Healthcare Stocks: Regencell Bioscience (RGC) led the healthcare stocks with an extraordinary YTD performance of +15,138.46%, followed by ABIVAX Société Anonyme (ABVX) and Cidara Therapeutics (CDTX) with +1,470.22% and +721.43%, respectively.
Quant Ratings Overview: GRAIL (GRAL) and Nuvation Bio (NUVB) received Strong Buy ratings with scores of 4.98 and 4.99, while most other companies in the top 10 list carried Hold ratings, indicating a mixed outlook for the sector.
Healthcare ETFs Mentioned: Various healthcare ETFs such as XLV, VHT, IHI, IXJ, IYH, FHLC, and FXH were noted, highlighting investment options within the healthcare sector.
Health Care ETFs Remain Unfazed by Price Reductions from Major Pharmaceutical Companies
Impact of Drug Pricing Deals: Big pharmaceutical companies are negotiating with the U.S. government to lower Medicaid drug prices, but analysts believe the financial impact on these companies may be less severe than initially feared.
Medicaid's Role in Drug Pricing: Medicaid accounts for about 10% of U.S. prescription drug spending and often secures significant discounts, which helps mitigate concerns over pricing pressures on pharmaceutical companies.
Resilience of Health Care ETFs: Diversified health care ETFs, such as the Health Care Select Sector SPDR Fund and Vanguard Health Care ETF, are performing well and provide a buffer against potential volatility from drug pricing news.
Pharma-Specific ETFs and Diversification: While specialized pharmaceutical ETFs may face more direct impacts from pricing negotiations, their diversified structures help reduce risks associated with individual companies, allowing them to remain stable amidst market fluctuations.
Healthcare ETFs Outperform Tech, Attract Billions as Investors Exit Due to Bubble Concerns
Healthcare Sector Rotation: A significant shift towards healthcare investments is occurring globally, with investors favoring sector ETFs, particularly in biotech and pharma, driven by strong performance in clinical trials and AI advancements.
Impact of Eli Lilly: Eli Lilly's recent achievement of a $1 trillion market cap has sparked enthusiasm in the healthcare sector, with its innovative products leading to substantial revenue growth and reshaping market expectations.
AI Integration in Healthcare: The integration of AI in healthcare is proving beneficial, with major companies like Lilly and Johnson & Johnson leveraging AI technologies to enhance drug discovery and surgical procedures, attracting investor interest in healthcare ETFs.
Sustained Investor Interest: The current healthcare investment trend reflects a recalibration rather than a temporary safety trade, as the sector combines defensiveness, innovation, and strong earnings momentum, making healthcare ETFs the primary beneficiaries.
Nasdaq Sees Strongest Performance Since May, Fueled by Alphabet's AI Surge: Implications for Thanksgiving Week Ahead.
Market Performance: U.S. stocks experienced a significant rebound on Monday, with the Nasdaq Composite index achieving its best performance since May, gaining 2.7%.
Recent Gains: The Nasdaq has seen a total increase of 3.6% since the market opened on Friday, marking its strongest two-day performance since mid-May.
CDC webpage states that the claim 'Vaccines do not cause autism' lacks evidence-based support.
CDC Webpage Update: The CDC has revised its webpage to indicate that vaccines may potentially contribute to autism, stating that previous claims asserting vaccines do not cause autism are not evidence-based and warrant further investigation.
Ongoing Investigations: The Department of Health and Human Services is conducting a comprehensive assessment of autism causes, exploring biological mechanisms that may link early childhood vaccinations to autism, including factors like aluminum adjuvants and neuroinflammation.
Political Context: The revision of the webpage comes amid political discussions, particularly during Health Secretary Robert F. Kennedy Jr.’s Senate confirmation process, where he assured that the CDC would not remove statements denying a vaccine-autism link.
Trust in CDC: The changes have raised concerns about the CDC's credibility as a scientific authority, leading to resignations of senior officials who cited the politicization of science within the agency.
